Pathophysiology and Pharmacology for Psychiatric Nurses in Caring Patients Receiving Antidepressant
Article Sidebar
Main Article Content
Abstract
Depression is a mood disorder that severely affects patients' thoughts, emotions, and behaviors. Without proper treatment, it may lead to self-harm or suicide. Pathophysiology involves imbalances in neurotransmitters, genetics, hormones, and the sleep-wake cycle.
This article reviews the biological mechanisms of depression and the pharmacology of antidepressants, including the newest drug classes such as Agomelatine and Esketamine. It compares their mechanisms of action, side effects, and nursing considerations. Additionally, it emphasizes the psychiatric nurse's role in providing comprehensive care based on the nursing process to prevent complications and reduce relapses.
This article highlights the importance of knowledge in pathophysiology and pharmacology to enhance the competency of psychiatric nurses in delivering comprehensive and safe care for patients with depression, especially when using newer antidepressants that require close monitoring and evaluation.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความหลังผ่านการปรับแก้จากกองบรรณาธิการแล้ว เป็นลิขสิทธ์ของวารสารจิตเวชวิทยาสาร โรงพยาบาลสวนปรุง กรมสุขภาพจิต กระทรวงสาธารณสุข ห้ามเผยแพร่เพื่อประโยชน์ทางการค้าโดยไม่ได้รับอนุญาต แต่อนุญาตให้เผยแพร่บทความดังกล่าวเพื่อประโยชน์ทางการศึกษาแก่ประชาชนทั่วไป ทั้งนี้กองบรรณาธิการไม่จำเป็นต้องเห็นด้วยกับบทความหรือข้อคิดเห็นใดๆ ที่ปรากฏในวารสารสวนปรุง
References
Ministry of Public Health. Percentage of patients with depression accessing mental health services [Internet]. 2023 [cited 2024 Jul 30]. Available from: https://healthkpi.moph.go.th/kpi2/kpi/index2/?kpi_year=2566
Chailap S. Theory and nursing process for individuals with grief, depression, and suicide risk. Bangkok: Chulalongkorn University Press; 2022. (In Thai)
Burden of Disease Research Program Thailand. Report of burden of disease and injuries among the Thai population in 2020. Nonthaburi: THE Graphico Systems; 2020.
Lalitanantapong D. Emergency psychiatry. Bangkok: Chulalongkorn University Printing House; 2018.
Chen XD, Li F, Zuo H, Zhu F. Trends in prevalent cases and disability-adjusted life-years of depressive disorders worldwide: findings from the Global Burden of Disease Study 1990 to 2021. Depress Anxiety. 2025;42(1):e5553491. doi:10.1002/da.23985
World Health Organization. Depression: let’s talk, says WHO, as depression tops list of causes of ill health [Internet]. Geneva: WHO; 2017 Mar 30 [cited 2024 Jul 30]. Available from: https://www.who.int/news/item/30-03-2017--depression-let-s-talk-says-who-as-depression-tops-list-of-causes-of-ill-health
Bains N, Abdijadid S, Miller JL. Major depressive disorder (nursing). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Apr 10 [cited 2024 Jul 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557845/
Xiang D, Xiao J, Sun S, Fu L, Yao L, Wang G, Liu Z. Differential regulation of DNA methylation at the CRMP2 promoter region between the hippocampus and prefrontal cortex in a CUMS depression model. Front Psychiatry. 2020 Mar 18;11:141. doi:10.3389/fpsyt.2020.00141
Cui L, Li S, Wang S, Wu X, Liu Y, Yu W, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024 Feb 9;9(1):30. doi:10.1038/s41392-024-01738-y
Tian H, Hu Z, Xu J, Wang C. The molecular pathophysiology of depression and the new therapeutics. MedComm. 2022;3:e156. doi:10.1002/mco2.156
Chiappetta L, Varcarolis EM. Mood disorders: depression. In: Varcarolis EM, Fosbre CD, editors. Essentials of psychiatric mental health nursing: a communication approach to evidence-based care. 4th ed. St Louis (MO): Elsevier; 2021. p. 199-226.
Kleebthong D, Chareonsuk S, Kristiansen L. Thai psychiatric nurses' experiences and perceptions of the professional role when caring for older people displaying depressive symptoms. Open J Nurs. 2018;8(1):45-59. doi:10.4236/ojn.2018.81005
Wathanasin D. Depression in adolescents: basic concepts and nursing care. 1st ed. Bangkok: Vanida Press; 2021. (In Thai)
Ju Y, Ou W, Chen H, Yang L, Long Y, Liang H, et al. Agomelatine as adjunctive therapy with SSRIs or SNRIs for major depressive disorder: a multicenter, double-blind, randomized, placebo-controlled trial. BMC Med. 2025 Mar 5;23(1):137. doi:10.1186/s12916-025-03766-w
Kamal M, Gbahou F, Guillaume JL, Daulat AM, Benleulmi-Chaachoua A, Luka M, et al. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers. J Biol Chem. 2015;290(18):11537-46. doi:10.1074/jbc.M114.628701
De Berardis D, Fornaro M, Serroni N, Campanella D, Rapini G, Olivieri L, et al. Agomelatine beyond borders: current evidence of its efficacy in disorders other than major depression. Int J Mol Sci. 2015 Jan 5;16(1):1111-30. doi:10.3390/ijms16011111
Schneider M, Pauwels P, Toto S, Bleich S, Grohmann R, Heinze M, et al. Severe weight gain as an adverse drug reaction of psychotropics: data from the AMSP project between 2001 and 2016. Eur Neuropsychopharmacol. 2020 Jan;36:60-71. doi:10.1016/j.euroneuro.2019.11.004
Swainson J, Thomas RK, Archer S, Chrenek C, MacKay MA, Baker G, et al. Esketamine for treatment resistant depression. Expert Rev Neurother. 2019 Oct;19(10):899-911. doi:10.1080/14737175.2019.1656023
Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med. 2023 Oct 5;389(14):1298-309. doi:10.1056/NEJMoa2304145
Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019 Sep 1;76(9):893-903. doi:10.1001/jamapsychiatry.2019.1189
Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019 Jun 1;176(6):428-38. doi:10.1176/appi.ajp.2019.19020172
Terburg D, van Honk J, Schutter DJLG. Doubling down on dual systems: a cerebellum–amygdala route towards action- and outcome-based social and affective behavior. Cortex. 2024 Jan;173:175-86. doi:10.1016/j.cortex.2024.01.004
Gledhill J, Hodes M. Management of depression in children and adolescents. Prog Neurol Psychiatry. 2015;19(2):28-33. doi:10.1002/pnp.364
Borbély É, Simon M, Fuchs E, Wiborg O, Czéh B, Helyes Z. Novel drug developmental strategies for treatment-resistant depression. Br J Pharmacol. 2022 Mar;179(6):1146-86. doi:10.1111/bph.15730
Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TT. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020 Dec;20:1-3. doi:10.1186/s12888-020-02977-0
Davidson M, Rashidi N, Nurgali K, Apostolopoulos V. The role of tryptophan metabolites in neuropsychiatric disorders. Int J Mol Sci. 2022 Sep 1;23(17):9968. doi:10.3390/ijms23179968
Bernaras E, Jaureguizar J, Garaigordobil M. Child and adolescent depression: a review of theories, evaluation instruments, prevention programs, and treatments. Front Psychol. 2019 Mar 22;10:543. doi:10.3389/fpsyg.2019.00543
Comai S, Gobbi G. Melatonin, melatonin receptors and sleep: moving beyond traditional views. J Pineal Res. 2024 Oct;76(7):e13011. doi:10.1111/jpi.13011
Segalàs C, Labad J, Salvat-Pujol N, Real E, Alonso P, Bertolín S, et al. Sleep disturbances in obsessive-compulsive disorder: influence of depression symptoms and trait anxiety. BMC Psychiatry. 2021 Dec;21:1-10. doi:10.1186/s12888-021-03541-7
Takwiriyanun N. Nursing psychiatric patients. 3rd ed. Bangkok: Thammasat University Press; 2020. (In Thai)
Agius M, Bonnici H. Antidepressants in use in clinical practice. Psychiatr Danub. 2017;29(Suppl 3):667-71.
Videbeck SL. Psychiatric-Mental Health Nursing. 8th ed. Philadelphia (PA): Wolters Kluwer; 2021.
Varchol DA. Biological basis for understanding psychopharmacology. In: Varcarolis EM, editor. Essentials of psychiatric mental health nursing: a communication approach to evidence-based care. 3rd ed. St Louis (MO): Elsevier; 2017. p. 34-51.
Mohan P, Singh H, Sinha S, Prabhakaran K. Pharmacological profile of prescriptions containing antidepressants. J Mar Med Soc. 2021 Jan-Apr;23(1):29. doi:10.4103/jmms.jmms_72_20
Briggs R, Carey D, McNicholas T, Claffey P, Nolan H, Kennelly SP, et al. The association between antidepressant use and orthostatic hypotension in older people: a matched cohort study. J Am Soc Hypertens. 2018 Aug;12(8):597-604. doi:10.1016/j.jash.2018.07.005
Rajhans P, Chadda RK. Treatment of depression. In: Gautam S, Avasthi A, editors. Drug therapy for psychiatric disorders. 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2020. p. 25-42.
Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020 Apr;212(7):329-34. doi:10.5694/mja2.50585
Pereira S, Brennan E, Patel A, Moran M, Wallier J, Liebowitz MR. Managing dissociative symptoms following the use of esketamine nasal spray: a case report. Int Clin Psychopharmacol. 2021 Jan;36(1):54-7. doi:10.1097/YIC.0000000000000349
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021 May 1;178(5):383-99. doi:10.1176/appi.ajp.2020.20030333
